Clin2
NCT04743141Possibly a fitRecruiting

Long-term migraine medicine study for kids with migraine attacks

Acute Treatment of Migraine

Treatments studied

Part of Brain & nervous system, Ear, nose & throat, Eyes & vision clinical trials.

This Phase 3 study checks the long-term safety of rimegepant, a migraine treatment, in children and teens. You might join if your child has had migraine for at least 6 months and still gets a certain number of moderate-to-severe migraine attacks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
600 people
Ages
6 years to 17 years
Study type
Interventional

Who can take part

  • Your child has had migraine (with or without aura) for at least 6 months
  • During the last 2 months, they had 1 to 8 moderate-to-severe migraine attacks per month
  • They have migraine days that need treatment during the study’s observation period
  • They are able to tell migraine from other types of headaches
  • They meet the age and weight limits (at least 6 years old, under 18; weight over 15 kg—EU teens 12–<18 may need over 25 kg)
  • They can have blood drawn (good vein access)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07685769Recruiting· Phase 4
Rimegepant safety study for adults with migraine in India

This study tests if the medicine rimegepant is safe for people with migraine. You may be able to join if you have had migraine for at least a year, have 4–14 migraine days per month, and have not had good results with other migraine medicines called triptans.

Bangalore, Karnataka
NCT07609914Recruiting· Phase 4
Safety study of an extra dose of rimegepant for migraine

This study tests whether taking an additional dose of rimegepant (a migraine medicine you may already use) is safe and helpful for adults with migraine. Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist—a type of medicine that blocks a protein involved in migraine pain.

Canoga Park, California
NCT06995729Recruiting· Phase 1
Testing zavegepant nasal spray in children with migraines

This trial tests whether the medicine zavegepant (given as a nasal spray) is safe and works well for children aged 6 to 11 who have a history of migraines. If your child gets migraines, this study may help find a new treatment option.

Little Rock, Arkansas
NCT06641466Recruiting· Phase 3
Study of Rimegepant for preventing menstrual migraine in women

This study tests whether the medicine rimegepant can help prevent migraines that happen around your period. It is for women with regular menstrual cycles who have a history of menstrual migraines.

Phoenix, Arizona
NCT05156398Recruiting· Phase 3
Rimegepant to prevent migraine attacks in children

This trial studies whether rimegepant can reduce how often migraine attacks happen in children and teens. It also looks at safety and how well the treatment fits day-to-day life and school activities.

Fort Smith, Arkansas
NCT04649242Recruiting· Phase 3
Migraine pain relief study for kids and teens

This trial studies a medicine for stopping a migraine attack in children and teens. It may help families understand which treatment works best during acute (during-attack) migraine pain.

Birmingham, Alabama

Hear when a new Acute Treatment of Migraine trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.